A major recall of atorvastatin, the generic version of Lipitor and the best-selling drug in the US, has been issued due to manufacturing defects that could reduce the medication's effectiveness. The recall, initiated by Ascend Laboratories on 19 September 2025, affects approximately 142,000 bottles of the cholesterol-lowering drug. The US Food and Drug Administration (FDA) classified the recall as Class II on 10 October, indicating that the defective tablets could cause temporary or medically reversible adverse health effects.
The issue stems from the tablets failing to dissolve properly during quality testing. Atorvastatin must dissolve in the body to be absorbed and reduce low-density lipoprotein (LDL) cholesterol, which is linked to cardiovascular events such as heart attacks and strokes. If the drug does not dissolve correctly, the amount absorbed is significantly reduced, potentially increasing the risk of such events. Studies have shown that stopping atorvastatin for six months can raise the risk of cardiovascular events by 12% to 15%.
Patients are advised not to stop taking their medication without consulting a pharmacist or prescriber, as even recalled pills are better than none. To check if their medication is affected, patients should look for 'MFG Ascend' or 'MFR Ascend' on their prescription label, or check the National Drug Code (NDC) starting with 67877. Pharmacists can cross-reference lot numbers with the FDA's recall list and may offer alternative generic versions of atorvastatin or other statins like rosuvastatin.
The recall highlights broader concerns about pharmaceutical manufacturing oversight. While Ascend Laboratories distributes the drug in the US, it is manufactured by Alkem Laboratories in India. Much of the world's drug production now occurs overseas, particularly in China and India, limiting the FDA's ability to conduct thorough inspections. This is the latest in a series of manufacturing quality issues since 2019, raising questions about the safety and reliability of the global drug supply chain.
